KVA-12123 is under clinical development by Kineta and currently in Phase II for Leiomyosarcoma. According to GlobalData, Phase II drugs for Leiomyosarcoma have a 17% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how KVA-12123’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KVA-12123 is under development for the treatment of solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), ovarian cancer (OC), renal cell carcinoma, melanoma and head and neck cancer squamous cell carcinoma, bladder cancer, leiomyosarcoma, colon cancer, transitional cell cancer (urothelial cell cancer), pancreatic cancer. It acts by targeting v-region immunoglobulin-containing suppressor of T cell activation (VISTA). It is administered through intravenous route as infusion. It was also under development for acute myelocytic leukemia (AML). It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope. It was under development for the treatment of hepatocellular carcinomas, squamous cell carcinoma of the skin and cervical cancer.
Kineta, formerly Yumanity Therapeutics Inc, is a clinical stage development company focused on the development of next-generation immunotherapies. Kineta has successfully established its Innate Immunity Development Platform with the purpose of creating fully human antibodies that target the key mechanisms responsible for cancer immune resistance. These mechanisms include immuno-suppression, exhausted T cells, and poor tumor immunogenicity. Its major pipeline products include KVA12123, Anti-CD27 agonist mAb immunotherapy and Anti-CD24 antagonistmAb immunotherapy. Kineta is headquartered in Seattle, Washington, the US.
For a complete picture of KVA-12123’s drug-specific PTSR and LoA scores, buy the report here.